10-Q: Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Lineage Cell Therapeutics reported a net loss of $6.5 million for the first quarter of 2024, with a decrease in collaboration revenue offset by a recent capital raise.

Summary

• Lineage Cell Therapeutics reported a net loss of $6.5 million for the first quarter of 2024, compared to a net loss of $4.4 million for the same period in 2023.
• The company's total revenue decreased to $1.4 million from $2.4 million year-over-year, primarily due to a decrease in collaboration revenue.
• Operating expenses totaled $8.1 million, a decrease from $9.0 million in the first quarter of 2023.
• Research and development expenses decreased to $3.0 million from $4.2 million year-over-year.
• General and administrative expenses increased slightly to $5.0 million from $4.7 million year-over-year.
• The company's cash, cash equivalents, and marketable securities totaled $43.6 million as of March 31, 2024.
• Lineage raised approximately $13.8 million in net proceeds through a registered direct offering of common shares in February 2024.
• The company believes its current cash and cash equivalents will be sufficient to fund operations for at least the next twelve months.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the company has secured funding and is progressing with clinical trials, the increased net loss and decreased revenue are concerning. The ongoing geopolitical risks also add a layer of uncertainty.

Positives

• Lineage successfully raised $13.8 million through a registered direct offering, strengthening its financial position.
• The company is actively progressing with its DOSED clinical study for OPC1, with the first clinical site expected to open in the second quarter of 2024.
• Lineage entered into a service agreement with Genentech to support the OpRegen program, indicating continued collaboration and potential for future revenue.
• Operating expenses decreased by 10% year-over-year, showing improved cost management.
• The company believes its current cash and cash equivalents will be sufficient to fund operations for at least the next twelve months.

Negatives

• The company experienced a net loss of $6.5 million in Q1 2024, an increase from the $4.4 million loss in Q1 2023.
• Total revenue decreased by 39% year-over-year, primarily due to a reduction in collaboration revenue.
• Research and development expenses decreased by 28%, which may indicate a slowdown in development activities.
• The review of the IND amendment for the DOSED study by the FDA is still ongoing due to workload and conflicting priorities at the agency.

Risks

• The company is subject to the ongoing Israel-Hamas war, which could materially and adversely impact its operations, financial condition, and operating results.
• The company's manufacturing processes are conducted in Jerusalem, Israel, making it vulnerable to disruptions from geopolitical conflicts.
• The company's ability to raise additional capital may be adversely impacted by unfavorable global economic conditions.
• The company is dependent on the success of its clinical trials and regulatory approvals, which are subject to inherent risks and uncertainties.
• The company's financial obligations include future payments to licensors and government entities, which are contingent and uncertain.

Future Outlook

The company expects to continue to incur losses for at least the next several years and anticipates that operating expenses will continue to increase as they progress with the development of their product candidates. They believe their current cash and cash equivalents will be sufficient to fund operations for at least the next twelve months.

Management Comments

• Management believes that the company's cash, cash equivalents, and marketable securities, together with projected cash flows, will be sufficient to carry out planned operations for at least twelve months.
• Management is focused on customary trial preparations and related activities to support opening the first clinical study site for the DOSED study in the second quarter of 2024.

Industry Context

Lineage Cell Therapeutics operates in the competitive biotechnology industry, focusing on allogeneic cell therapies. The company's collaboration with Roche and the development of its proprietary cell-based technology platform are key differentiators. The ongoing Israel-Hamas war introduces a unique geopolitical risk factor that could impact the company's operations and financial stability.

Comparison to Industry Standards

• Lineage's Q1 2024 net loss of $6.5 million is not unusual for a clinical-stage biotechnology company, as these companies typically incur significant losses during the development phase.
• The decrease in research and development expenses may be a concern, as it could indicate a slowdown in development activities, which is not typical for companies in this sector.
• The company's cash position of $43.6 million is relatively strong compared to other companies of similar size, providing a buffer for ongoing operations and clinical trials.
• The collaboration with Roche is a significant positive, as it provides a source of revenue and validation of the company's technology, which is a common strategy for biotech companies.
• The company's reliance on manufacturing in Israel introduces a unique risk factor not typically seen in other biotech companies, which are often geographically diversified.

Management Changes

Legal Proceedings

• The company is currently not a party to any material legal proceedings.
• The company is subject to a request for disclosure of documents by HBL Hadasit Bio-Holdings Ltd. related to the validity of an intercompany agreement.

Related Party Transactions

• Lineage has incurred approximately $626,000 in legal expenses on behalf of Neal Bradsher, Broadwood Partners, L.P., and Broadwood Capital, Inc.
• Broadwood Partners, L.P., purchased 6,730,770 common shares in a registered direct offering, and Don Bailey purchased approximately 96,155 shares in the same offering.

Stakeholder Impact

• Shareholders may be concerned about the increased net loss and decreased revenue.
• Employees may be affected by the ongoing Israel-Hamas war and potential disruptions to operations.
• Customers and partners may be impacted by potential delays in clinical trials and product development.
• Creditors may be concerned about the company's financial performance and ability to meet its obligations.

Next Steps

• The company intends to continue to work closely with the FDA to respond to any additional information requests and/or feedback regarding the DOSED study.
• Lineage will continue to focus on customary trial preparations and related activities to support opening the first clinical study site for the DOSED study in the second quarter of 2024.
• The company will continue to advance its pipeline of allogeneic cell therapy programs.

Key Dates

Keywords

cell therapy, clinical trials, biotechnology, OpRegen, OPC1, financial results, collaboration, research and development, capital raise, FDA